BURROUGHS WELLCOME's DETAILS ON ZOVIRAX PATIENT EDUCATION PROGRAM REQUESTED
This article was originally published in The Tan Sheet
Executive Summary
BURROUGHS WELLCOME's DETAILS ON ZOVIRAX PATIENT EDUCATION PROGRAM REQUESTED for the upcoming joint meeting of FDA's Antiviral Drugs and Nonprescription Drugs Advisory Committees by OTC committee member Alan Sinaiko, MD, University of Minnesota. At a May 19 joint session of the committees, Sinaiko asked that Burroughs Wellcome present "their plan for [consumer] education" on OTC Zovirax (acyclovir) on July 28, the date tentatively set by FDA for the committees to review the Rx-to-OTC switch of the drug.